ZJAMP.(SZ:002758) Zheng Quan Zhi Xing·2025-06-03 10:29Transaction Overview - Zhejiang Nong Group Co., Ltd. is transferring 100% equity of its wholly-owned subsidiary, Zhejiang Huato Pharmaceutical Group Co., Ltd. (Huato Pharmaceutical), through a public listing on the Zhejiang Stock Exchange [1][2] - The transfer price is set at 36,910.00 million RMB, which aligns closely with the asset valuation of 36,909.52 million RMB determined by an asset appraisal report [2][3] - The transaction does not require shareholder approval as it does not constitute a major asset restructuring under relevant regulations [1][3] Financial Assessment - As of December 31, 2024, Huato Pharmaceutical's total assets were valued at 56,206.95 million RMB, with an assessed value of 74,847.00 million RMB, resulting in a value increase of 18,640.05 million RMB, or 33.16% [2] - The net asset value was assessed at 36,909.52 million RMB, reflecting a 102.03% increase from its book value of 18,269.47 million RMB [2] Buyer Information - The buyer, Zhejiang Yinte Pharmaceutical Co., Ltd., is a limited liability company established on October 28, 1998, with a registered capital of 42,600.00 million RMB [3][4] - Yinte Pharmaceutical is fully owned by Zhejiang Yinte Group Co., Ltd. and has no related party transactions with Zhejiang Nong Group [6] Purpose and Impact of the Transaction - The transaction aims to optimize resource allocation, enhance operational efficiency, and focus on the core business of agricultural comprehensive services [10] - Post-transaction, Huato Pharmaceutical will no longer be included in the consolidated financial statements of Zhejiang Nong Group, which is expected to improve the company's profitability and core competitiveness [10]